438 related articles for article (PubMed ID: 15660959)
21. Molecular dissection of G protein preference using Gsalpha chimeras reveals novel ligand signaling of GPCRs.
Hsu SH; Luo CW
Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1021-9. PubMed ID: 17652154
[TBL] [Abstract][Full Text] [Related]
22. Relaxin-3, INSL5, and their receptors.
Liu C; Lovenberg TW
Results Probl Cell Differ; 2008; 46():213-37. PubMed ID: 18236022
[TBL] [Abstract][Full Text] [Related]
23. Cellular and molecular biology of orphan G protein-coupled receptors.
Oh DY; Kim K; Kwon HB; Seong JY
Int Rev Cytol; 2006; 252():163-218. PubMed ID: 16984818
[TBL] [Abstract][Full Text] [Related]
24. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
Huber T; Menon S; Sakmar TP
Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
[TBL] [Abstract][Full Text] [Related]
25. Optical techniques to analyze real-time activation and signaling of G-protein-coupled receptors.
Lohse MJ; Nikolaev VO; Hein P; Hoffmann C; Vilardaga JP; Bünemann M
Trends Pharmacol Sci; 2008 Mar; 29(3):159-65. PubMed ID: 18262662
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease.
Thompson MD; Cole DE; Jose PA
Methods Mol Biol; 2008; 448():77-107. PubMed ID: 18370232
[TBL] [Abstract][Full Text] [Related]
27. Interactions between G-protein-coupled receptors and periplakin: a selective means to regulate G-protein activation.
Milligan G; Murdoch H; Kellett E; White JH; Feng GJ
Biochem Soc Trans; 2004 Nov; 32(Pt 5):878-80. PubMed ID: 15494039
[TBL] [Abstract][Full Text] [Related]
28. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities.
De Amici M; Dallanoce C; Holzgrabe U; Tränkle C; Mohr K
Med Res Rev; 2010 May; 30(3):463-549. PubMed ID: 19557759
[TBL] [Abstract][Full Text] [Related]
29. Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities.
Seifert R; Dove S
Mol Pharmacol; 2009 Jan; 75(1):13-8. PubMed ID: 19001067
[TBL] [Abstract][Full Text] [Related]
30. Structural diversity of G protein-coupled receptors and significance for drug discovery.
Lagerström MC; Schiöth HB
Nat Rev Drug Discov; 2008 Apr; 7(4):339-57. PubMed ID: 18382464
[TBL] [Abstract][Full Text] [Related]
31. An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application.
Kratochwil NA; Malherbe P; Lindemann L; Ebeling M; Hoener MC; Mühlemann A; Porter RH; Stahl M; Gerber PR
J Chem Inf Model; 2005; 45(5):1324-36. PubMed ID: 16180909
[TBL] [Abstract][Full Text] [Related]
32. The changing world of G protein-coupled receptors: from monomers to dimers and receptor mosaics with allosteric receptor-receptor interactions.
Fuxe K; Marcellino D; Borroto-Escuela DO; Frankowska M; Ferraro L; Guidolin D; Ciruela F; Agnati LF
J Recept Signal Transduct Res; 2010 Oct; 30(5):272-83. PubMed ID: 20684666
[TBL] [Abstract][Full Text] [Related]
33. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling.
Luttrell LM; Kenakin TP
Methods Mol Biol; 2011; 756():3-35. PubMed ID: 21870218
[TBL] [Abstract][Full Text] [Related]
34. A constitutively active GPCR retains its G protein specificity and the ability to form dimers.
Ladds G; Davis K; Das A; Davey J
Mol Microbiol; 2005 Jan; 55(2):482-97. PubMed ID: 15659165
[TBL] [Abstract][Full Text] [Related]
35. Reversible translocation of p115-RhoGEF by G(12/13)-coupled receptors.
Meyer BH; Freuler F; Guerini D; Siehler S
J Cell Biochem; 2008 Aug; 104(5):1660-70. PubMed ID: 18320579
[TBL] [Abstract][Full Text] [Related]
36. New insights from structural biology into the druggability of G protein-coupled receptors.
Mason JS; Bortolato A; Congreve M; Marshall FH
Trends Pharmacol Sci; 2012 May; 33(5):249-60. PubMed ID: 22465153
[TBL] [Abstract][Full Text] [Related]
37. Asymmetric conformational changes in a GPCR dimer controlled by G-proteins.
Damian M; Martin A; Mesnier D; Pin JP; Banères JL
EMBO J; 2006 Dec; 25(24):5693-702. PubMed ID: 17139258
[TBL] [Abstract][Full Text] [Related]
38. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
[TBL] [Abstract][Full Text] [Related]
39. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.
Leach K; Sexton PM; Christopoulos A
Trends Pharmacol Sci; 2007 Aug; 28(8):382-9. PubMed ID: 17629965
[TBL] [Abstract][Full Text] [Related]
40. Are vasoactive neuropeptide autoimmune fatigue-related disorders mediated via G protein-coupled receptors?
Staines D
Med Hypotheses; 2005; 65(1):29-31. PubMed ID: 15893112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
